Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of CNTO 328 in Relapsed or Refractory Multiple Myeloma
2006-001897-26Phase 2Completed
- Sponsor
- Janssen Biotech
- Start
- Jul 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of siltuximab in multiple myeloma (MM) (2 arms), sponsored by Janssen Biotech. Primary endpoints: Primary endpoint - overall response rate with CNTO 328 if Treatment Plan B is not used and Primary endpoint - overall response rate with CNTO 328 plus dexamethasone (Treatment Plan B). Started Jul 2006; status: completed.
02
Drugs
siltuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2006-001897-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001897-26.